The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.
Related Posts
Exxon earnings beat, increases fourth-quarter dividend
Exxon’s stock rose in early trading after beating earnings expectations.
CEOs think Trump’s tariff plan is a ‘huge mistake,’ says Altimeter’s Brad Gerstner
Altimeter Capital’s CEO said on “Halftime Report” that the new tariff policies “look like protectionism” and could damage the economy.
Expect China to help Trump on fentanyl, TikTok and midterm elections, says Evercore ISI strategist
“We expect Beijing to please Trump in a way that benefits the Republican party in midterm election, whether via purchases or investment,” the strategist said.